BMO Capital analyst Jenny Ma maintains H&R REIT (TSX:HR) with a Outperform and lowers the price target from C$17 to C$15.5.
Epilepsy-Focused MedTech NeuroPace Has Attractive Entry Point, Competitive Position
Cantor Fitzgerald initiated coverage on NeuroPace Inc (NASDAQ: NPCE), a commercial-stage medical device company focused on drug-resistant epilepsy treatment through the company's responsive neurostimulation device (RNS).
